Cidel Asset Management Inc. Increases Stock Position in Zoetis Inc. $ZTS

Cidel Asset Management Inc. raised its stake in Zoetis Inc. (NYSE:ZTS) by 47.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,895 shares of the company’s stock after acquiring an additional 48,033 shares during the period. Cidel Asset Management Inc.’s holdings in Zoetis were worth $17,719,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the company. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis in the fourth quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new position in shares of Zoetis during the fourth quarter worth about $25,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis in the 3rd quarter valued at about $31,000. Finally, Holos Integrated Wealth LLC acquired a new position in Zoetis in the 4th quarter valued at about $32,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 1.3%

NYSE ZTS opened at $76.85 on Wednesday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The stock has a market capitalization of $32.22 billion, a P/E ratio of 12.74, a P/E/G ratio of 1.18 and a beta of 0.75. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $161.77. The firm has a 50-day moving average price of $91.31 and a 200 day moving average price of $111.78.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the firm posted $1.48 EPS. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. Zoetis’s payout ratio is 35.16%.

Insider Buying and Selling

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 11,650 shares of company stock valued at $886,384 over the last quarter. Company insiders own 0.22% of the company’s stock.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Pomerantz, Howard G. Smith, Rosen, Kessler Topaz, Glancy Prongay Wolke & Rotter, the Gross Law Firm, and Schall Law Firm all issued notices about a class action lawsuit and July 27 lead-plaintiff deadline for Zoetis investors, keeping legal risk in focus. Article: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors…
• Negative Sentiment: Another report said Zoetis shareholders who lost money may seek to lead a securities-fraud lawsuit, adding to the overhang on the stock. Article: Zoetis Inc. (ZTS) Shareholders Who Lost Money…
• Neutral Sentiment: Brokerage commentary still shows an average Hold rating, suggesting analysts are not broadly turning bullish yet. Article: Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Hold”…

Analyst Ratings Changes

A number of analysts have weighed in on ZTS shares. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Argus reissued a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Morgan Stanley restated an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research note on Friday, May 15th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, UBS Group lowered their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $133.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.